Adicet Bio reduces workforce 30%, discontinues ADI-270, extends cash runway into Q4 2026

Adicet Bio, Inc.

Workforce reduction of ~30%; expects $2.3M in severance costs in Q3 2025.
Discontinued ADI-270 for ccRCC; focus shifts to ADI-001 (autoimmune) and ADI-212 (PSMA).
ADI-270 Phase 1 data: 100% disease control rate, 20% response rate; no cytokine release syndrome.
Restructuring and program cuts expected to extend cash runway into Q4 2026.
ADI-212 is an optimized next-generation gene-edited, cytokine-armored CAR T targeting PSMA.

item 2.05item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.